Cordis Receives FDA Clearance for Vascular Stent Systems for Use in SFA
Cordis Corp. has announced it has received FDA clearance for its S.M.A.R.T. CONTROL vascular stent systems for use in the superficial femoral artery and/or the proximal popliteal artery, according to a news release.
Cordis, part of the Johnson & Johnson family of companies, said the S.M.A.R.T. stent is the first stent in the Unites States with both iliac and SFA indications.
"We are very pleased to offer an expanded indication for the S.M.A.R.T. stent," said Shlomi Nachman, worldwide president of Cordis, in the release. "Our goal is to continue to make expanded indications and new products available to our customers so they may bring these innovations to their patients."
Related Articles on FDA Clearances:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- The Future of ACOs for Anesthesiologists
- Healthcare Exchange Traded Funds See Biggest Boom in Years
- FDA Issues Draft Guidance on Off-Label Use Information Dissemination
- Surgical Care Affiliates President & CEO Andrew Hayek Among 2014 Aspen Institute Henry Crown Fellows
- A Look at ASC Valuation Through the Eyes of M&D Companies